- Tipos de Cáncer
Tipos de Cáncer
Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.A a la Z - Tratamiento
Tratamiento del Cáncer
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
- Riesgo de concer y prevencion
- Drogas de Cáncer
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
- Lidiando
Lidiando con el Cáncer
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
- Profesionales de la salud
- Estudios Clínicos
Notas para enfermeros 
¿Cuál es mi riesgo? k? 
OncoPilot: Manejando su experiencia del cáncer 
OncoLink Cancer Blogs
Community Events Calendar 
Abramson Cancer Center 
NCI CANCERLIT® Search: Tuberous Sclerosis - July 2002
National Cancer Institute®
Ultima Vez Modificado: 1 de julio del 2002
- Novel TSC1 and TSC2 mutations in Japanese patients with tuberous sclerosis complex.
- Focal cortical dysplasia of Taylor's balloon cell type: mutational analysis of the TSC1 gene indicates a pathogenic relationship to
- Bourneville and Taylor: a developing story?
Table of Contents
1
UI - 12015165
AU - Yamamoto T; Pipo JR; Feng JH; Takeda H; Nanba E; Ninomiya H; Ohno K
TI -
Novel TSC1 and TSC2 mutations in Japanese patients with tuberous
sclerosis complex.
SO - Brain Dev 2002 Jun;24(4):227-30
AD - Gene Research Center, Tottori University, Yonago 683-8503, Japan.
tyamamot@grape.med.tottori-u.ac.jp
Tuberous sclerosis complex (TSC) is a neurocutaneous syndrome
characterized by development of unusual tumor-like growths. Involvement
of the brain is associated with the most problematic clinical
manifestations of TSC, including intellectual retardation, epilepsy and
abnormal behaviors. Until now, over 300 mutations of TSC1 and TSC2 were
reported. Here, we report one novel mutation of TSC1 (Q897X) and five
novel mutations of TSC2 (c.336+1 G>A, L345R, E700K, R905G, K914K)
identified in Japanese patients with TSC. We also identified three new
polymorphisms in TSC2 (N331N, A431A, S802G). The TSC1 mutation was
predicted to cause a nonsense substitution whereas all of the five TSC2
mutations were predicted to cause either a splicing error or a missense
substitution. In accordance with previous findings, the patients with
TSC1 mutations had milder clinical manifestations than those with TSC2
mutations.
2
UI - 12112044
AU - Becker AJ; Urbach H; Scheffler B; Baden T; Normann S; Lahl R; Pannek HW;
TI -
Tuxhorn I; Elger CE; Schramm J; Wiestler OD; Blumcke I
Focal cortical dysplasia of Taylor's balloon cell type: mutational
analysis of the TSC1 gene indicates a pathogenic relationship to
tuberous sclerosis.
SO - Ann Neurol 2002 Jul;52(1):29-37
AD - Department of Neuropathology, FE Neuroradiology, University of Bonn
Medical Center, Bonn, Germany.
Focal cortical dysplasia (FCD) is characterized by a localized
malformation of the neocortex and underlying white matter. Balloon
cells, similar to those observed in tuberous sclerosis, are present in
many cases (FCD(bc)). In these patients, a hyperintense funnel-shaped
subcortical lesion tapering toward the lateral ventricle was the
characteristic finding on fluid-attenuated inversion recovery magnetic
resonance imaging scans. Surgical lesionectomy results in complete
seizure relief. Although the pathogenesis of FCD(bc) remains uncertain,
histopathological similarities indicate that FCD(bc) may be related
pathogenetically to tuberous sclerosis. Here, we studied alterations of
the TSC1 and TSC2 genes in a cohort of patients with chronic, focal
epilepsy and histologically documented FCD(bc) (n = 48). DNA was
obtained after microdissection and laser-assisted isolation of balloon
cells, dysplastic neurons, and nonlesional cells from adjacent normal
brain tissue. Sequence alterations resulting in amino acid exchange of
the TSC1 gene product affecting exons 5 and 17 and silent base exchanges
in exons 14 and 22 were increased in patients with FCD(bc) compared with
200 control individuals (exon 5, 2.3% FCD(bc) vs 0% C; exon 17, 35%
FCD(bc) vs 1.0% C; exon 14, 37.8% FCD(bc) vs 15% C; exon 22, 45% FCD(bc)
vs 23.8% C). Sequence alterations could be detected in FCD(bc) and in
adjacent normal cells. In 24 patients, DNA was suitable to study loss of
heterozygosity at the TSC1 gene locus in microdissected FCD(bc) samples
compared with control tissue. Eleven FCD(bc) cases exhibited loss of
heterozygosity. In the TSC2 gene, only silent polymorphisms were
detected at similar frequencies as in controls. Our findings indicate
that FCD(bc) constitutes a clinicopathological entity with distinct
neuroradiological, neuropathological, and molecular genetic features.
These data also suggest a role of the TSC1 gene in the development of
FCD(bc) and point toward a pathogenic relationship between FCD(bc) and
the tuberous sclerosis complex.
3
UI - 12112041
AU - Crino PB
TI -
Bourneville and Taylor: a developing story?
SO - Ann Neurol 2002 Jul;52(1):6-9
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
